The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is ...

‘Apixaban drug found to substantially reduce the risk of dangerous bleeding in atrial fibrillation patients when compared to warfarin drug.’ The study, published online today in ...

It appears that apixaban will be an excellent treatment for the many patients with atrial fibrillation who are ... reducing stroke but is a difficult drug to use because of numerous interactions ...

In patients with atrial fibrillation for whom vitamin ... the rates of permanent discontinuation of the study medication were 17.9% per year in the apixaban group and 20.5% per year in the aspirin ...

Apixaban oral tablet is available as a brand-name drug. It doesn’t have a generic ... It also helps to lower risk of stroke if you have atrial fibrillation without an artificial heart valve.

"Our study mirrored the ARISTOTLE trial in that apixaban proved to be a better blood -thinning medication for all patients with atrial fibrillation," Flaker said. "We looked at the specific drug ...

Data sources: EMBASE and MEDLINE were searched (up to June 2012) combining medication names ... Cause in Patients with Atrial Fibrillation/Atrial Flutter AVERROES Apixaban Versus Acetylsalicylic ...

did not receive at least one dose of a trial medication. Apixaban or aspirin was permanently discontinued during follow-up owing to the development of subclinical atrial fibrillation lasting more ...

apixaban in patients with atrial fibrillation despite less bleeding ... “Importantly, that may speak to the dose of the drug used in this study and may speak to how much activity inhibition ...

Those suffering from atrial fibrillation, can now breathe a ... that doctors in England and Wales prescribe a new drug called “apixaban”, which is being marketed under the brand name Eliquis.

The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.